Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced an oral podium presentation and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023), being held May 30 – June 2, 2023, in Miami, Fla. Copies of the presentations will be made available on the Zynerba corporate website following the presentations at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024

Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome

Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th Gatlinburg Conference

DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of two posters at the 55th Gatlinburg Conference, being held April 10-13, 2023, in Kansas City, Mo. Copies of the posters will be made available on the Zynerba corporate website following the presentation at www.zynerba.com/publications.

Zynerba Pharmaceuticals Announces Poster Presentations at the 55th Gatlinburg Conference

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today issued a statement confirming that it does not hold cash deposits or securities at Silicon Valley Bank.

Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank

DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 4:40 p.m. ET, and host investor meetings.

Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at Cowen's 43rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:50 p.m. ET, and host investor meetings. The conference is being held at the Boston Marriott Copley Place in Boston, Mass.

Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference

Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS)

Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome

CuriosityStream

LendingClub

Manitex

Root

Want to try a different approach? Tap five stocks with increasing P/E ratios.

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has revised its timeline for releasing topline results from its multiple-centre Phase 3 RECONNECT trial, which sees Zygel administered to children and adolescents aged from three to 17 to treat symptoms of Fragile X syndrome (FXS). The pharma group said factors including the so-called 'Tripledemic' (high rates of respiratory syncytial virus (RSV), influenza and COVID-19) had led to higher-than-expected cancellations of initial screening visits at the trial's investigational centers, leading to slower-than-anticipated enrollment.

Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome

RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024

Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Arizona. The poster, titled 'An Open-Label Tolerability and Efficacy Study of ZYN002 (cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE)', shows that through 38 weeks of treatment, statistically significant improvements were seen in children and adolescents treated with Zygel in the Pediatric Anxiety Rating Scale (PARS-R), all five scales of the Anxiety, Depression and Mood Scale (ADAMS), and all five subscales of the Aberrant Behavior Checklist – Community (ABC-C).

Zynerba Pharmaceuticals announces positive long-term data from Phase 2 INSPIRE trial at annual meeting of the American College of Neuropsychopharmacology

Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology

DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Ariz. A copy of the poster will be made available on the Zynerba corporate website following the presentation at www.zynerba.com/publications.

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced that Fragile X patients treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with a placebo in a recent Phase 3 trial. Results from the Phase 3 CONNECT-FX study of Zygel for the treatment of behavioral symptoms in children and adolescents with Fragile X syndrome (FXS) were published in the Journal of Neurodevelopmental Disorders, the company said.

Zynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X patients in phase 3 trial

Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reported it has further advanced its transdermal gel Zygel—receiving orphan drug designation from the European Commission (EC) for the gel's active ingredient to treat 22q11.2 deletion syndrome (22q). Zygel, which contains cannabidiol, was previously granted orphan drug designation by the EC for the treatment of Fragile X syndrome (FXS).

Zynerba Pharmaceuticals granted orphan drug designation by EC for Zygel active ingredient to treat 22q

DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, Zygel™, for the treatment of 22q11.2 deletion syndrome (22q).

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), which works on innovative pharmaceutically produced transdermal cannabinoid therapies for neuropsychiatric disorders, posted results for the third quarter that revealed ample cash on hand, giving the company scope to fund pivotal trials of its flagship product Zygel (ZYN002). As of September 30, 2022, the Devon, Pennsylvania-based company had cash and equivalents of $55.9 million, compared to $67.8 million at the end of December 2021.

Zynerba ends 3Q with robust $55.9M cash runway to advance its Zygel CBD Gel for Fragile X Syndrome

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023

Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has announced that the US Patent and Trademark Office has issued Patent No. 11,458,109, titled "Treatment of 22q11.2 Deletion Syndrome With Cannabidiol," which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2 deletion syndrome with cannabidiol.

Zynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product candidate, Zygel

DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,109, titled “Treatment of 22q11.2 Deletion Syndrome With Cannabidiol,” which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2 deletion syndrome with cannabidiol.

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022, in Washington DC.  The poster, titled ‘An Open-Label Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE)', reports data from the first 14-week treatment period that suggests a positive risk-benefit profile for Zynerba's cannabidiol-formulated gel Zygel in improving anxiety-related and behavioral symptoms in children and adolescents with 22q11.2 deletion syndrome (22q).

Zynerba Pharma presents positive data from Phase 2 INSPIRE trial at NORD Rare Diseases and Orphan Products Breakthrough Summit

DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022 in Washington, D.C. A copy of the poster will be made available on the Zynerba corporate website following the presentation at www.zynerba.com/publications.

Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

News for Zynerba Pharmaceuticals Stock (ZYNE)